title: Surgery and imatinib therapy for liver oligometastasis of GIST: a study of Japanese Study Group on GIST.
abstract: We conducted a multicenter prospective study to clarify the efficacy and safety of surgery and imatinib for liver oligometastasis of gastrointestinal stromal tumors. Eligible gastrointestinal stromal tumor patients were enrolled in the surgery trial or the imatinib trial. Primary endpoints were recurrence-free survival and progression-free survival, respectively. The trials were prematurely terminated due to amendment of guidelines for adjuvant imatinib therapy and low patient accrual. In the surgery trial, all the six patients showed hepatic recurrence: median recurrence-free survival was 145 days (range: 62-1366 days). Of the five patients receiving salvage imatinib therapy, two showed progressive disease although no death was observed. Of the five patients enrolled in the imatinib trial, one died of pneumonia after progressive disease, and four had not shown progressive disease as of last visit. The results suggest that liver oligometastasis of gastrointestinal stromal tumor may not be controllable by surgery alone and require concomitant imatinib therapy.
authors.affiliation: Department of Surgery, Sanjo General Hospital, Sanjo, Japan.
authors.forename: Tatsuo
authors.initials: T
authors.lastname: Kanda
authors.affiliation: Department of Surgery, Osaka Police Hospital, Osaka, Japan.
authors.forename: Toru
authors.initials: T
authors.lastname: Masuzawa
authors.affiliation: Department of Digestive Surgery, Kawasaki Medical School, Kurashiki, Japan.
authors.forename: Toshihiro
authors.initials: T
authors.lastname: Hirai
authors.affiliation: Department of Surgery, Kyoto Second Red Cross Hospital, Kyoto, Japan.
authors.forename: Osamu
authors.initials: O
authors.lastname: Ikawa
authors.affiliation: Department of Gastrointestinal Surgery, Hakodate Goryoukaku Hospital, Hakodate, Japan.
authors.forename: Akinori
authors.initials: A
authors.lastname: Takagane
authors.affiliation: Department of Radiology, Kochi Health Sciences Center, Kochi, Japan.
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Hata
authors.affiliation: Department of Surgery, Gunma Prefectural Cancer Center, Ota, Japan.
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Ojima
authors.affiliation: Department of Surgery, Nagano Red Cross Hospital, Nagano, Japan.
authors.forename: Harutsugu
authors.initials: H
authors.lastname: Sodeyama
authors.affiliation: Department of Surgery, Iwate Prefectural Central Hospital, Morioka, Japan.
authors.forename: Izumi
authors.initials: I
authors.lastname: Mochizuki
authors.affiliation: Department of Medical Informatics, Niigata University Medical and Dental Hospital, Niigata, Japan.
authors.forename: Takashi
authors.initials: T
authors.lastname: Ishikawa
authors.affiliation: Translational Research Informatics Center, Foundation for Biomedical Research and Innovation, Kobe, Japan.
authors.forename: Tatsuo
authors.initials: T
authors.lastname: Kagimura
authors.affiliation: National Cancer Center Hospital, Tokyo, Japan.
authors.forename: Toshirou
authors.initials: T
authors.lastname: Nishida
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018572:Disease-Free Survival; D005260:Female; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy* / Q000601:surgery*; D006498:Hepatectomy / Q000379:methods; D006801:Humans; D000068877:Imatinib Mesylate / Q000627:therapeutic use*; D007564:Japan; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary* / Q000601:surgery / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011446:Prospective Studies; D016879:Salvage Therapy
chemical_list: D000970:Antineoplastic Agents; D000068877:Imatinib Mesylate
keywords: GIST; hepatectomy; imatinib; liver metastasis; survival